✦ LIBER ✦

Surrogate endpoints in chemoprevention of breast cancer: Guidelines for evaluation of new biomarkers

✍ Scribed by Susan G. Hilsenbeck; Gary M. Clark

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 579 KB
Volume: 53
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.240531138

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II chemoprevention trial design

A phase II chemoprevention trial design to identify surrogate surrogate endpoint biomarkers in breast cancer

✍ Kapil Dhingra 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

Surrogate biomarkers for risk assessment and efficacy of potential chemopreventive agents are needed to improve the efficiency and reduce the cost of conducting chemoprevention trials. In addition to criteria of sensitivity, specificity, quantifiability, and reproducibility applicable to most potent

Modulation of DNA hypomethylation as a s

Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer

✍ Lianhui Tao; Wei Wang; Paula M. Kramer; Ronald A. Lubet; Vernon E. Steele; Micha 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

## Abstract Surrogate end‐point biomarkers are being developed as indicators of the efficacy of chemopreventive agents. These biomarkers are molecular and biological end‐points that can be modulated by chemopreventive agents in accordance with their efficacy to prevent cancer. DNA hypomethylation i

Subjects and recruitment strategies for

Subjects and recruitment strategies for a short-term phase II chemoprevention trial of breast cancer using surrogate endpoint biomarkers

✍ Victor G. Vogel 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Progression of breast neoplasia is characterized by a variety of causal and nonspecific molecular, karyotypic, and cellular level genetic alterations. These include allelic losses, chromosomal rearrangements, and aneusomies, as well as widely divergent clonal DNA content aberrations. Establishment o

Strategies for the application of biomar

Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials

✍ Kapil Dhingra; Victor Vogel; Nour Sneige; Aysegul Sahin; Marcelo Aldaz; Gabriel 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 648 KB

Current chemoprevention trial designs based on epidemiological risk assessment and occurrence of cancer as an endpoint are inefficient and expensive. Novel biomarkers are needed to facilitate the development of chemopreventive interventions. The following four categories of biomarkers may be useful

Assessment of DNA flow cytometry as a su

Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial

✍ Silvia Bruno; Rosalba Torrisi; Massimo Costantini; Laura Baglietto; Vincenzo Fon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

Although conventional cytology represents the most widely performed cytometric analysis of bladder cancer cells, DNA flow cytometry has, over the past decade, been increasingly used to evaluate cell proliferation and DNA ploidy in cells from bladder washings. We have investigated whether DNA flow cy

Clinical development of estrogen modulat

Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women

✍ Julia A. Lawrence; Phyllis B. Malpas; Caroline C. Sigman; Gary J. Kelloff 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

Tamoxifen has proven to be beneficial in the chemoprevention of breast cancer in women at increased risk for the disease. Other compounds that mediate the estrogen pathway remain to be tested for clinical efficacy. The mechanism of action, efficacy, and dose response of the estrogen modulators is de